Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Medigen Biotechnology. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Medigen Biotechnology's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medigen Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Medigen Biotechnology's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Medigen Biotechnology's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to compare Medigen Biotechnology's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Unable to determine if Medigen Biotechnology is high growth as no earnings estimate data is available.
Unable to determine if Medigen Biotechnology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Medigen Biotechnology's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Medigen Biotechnology's finances.
The net worth of a company is the difference between its assets and liabilities.
Medigen Biotechnology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Medigen Biotechnology's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
Medigen Biotechnology's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. Shi-Chung Chang, also known as Stanley, MD, PhD., serves as the Chairman and Chief Executive Officer of Medigen Biotechnology Corporation. Dr. Chang served as Managing Director of Medigen Biotechnology Corporation. He was a Doctor of Taiwan University Hospital. He served as the Chairman of Medicine Department of Tzu-Chi Medical College. He has been the Chairman of the Scientific Advisory Board at Lanka Graphite Limited since May 20, 2016. He has been a Non-Executive Director of TBG Diagnostics Limited since December 7, 2015. He serves as a Director of Development Center for Biotechnology, GeneTrol Biotherapeutics, Inc. and Medigreen Biotechnology Corporation. He served as a Director at Progen Pharmaceuticals Limited since December 7, 2015. He served as a Non-Executive Director of Progen Pharmaceuticals Limited from February 2001 to January 17, 2007. Dr. Chang holds an M.D. from the College of Medicine at the National Taiwan University and a Ph.D. in Laser Physics and Laser Biology from the Department of Surgery, University College London Medical School at the University of London, United Kingdom.
Insufficient data for Stanley to compare compensation growth.
Insufficient data for Stanley to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Chairman and Chief Executive Officer
President & Director
Chief Financial Officer
President of Vaccine Business
Board of Directors
President & Director
Chairman and Chief Executive Officer
Jing Di Wu
Shang Yi Cai
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Medigen Biotechnology Corp. focuses on the development of therapies for liver diseases and cancers in Taiwan. The company is developing PI-88 (MUPAFOSTAT) for the treatment of liver cancer; PI-88 (MUPARFOSTAT) that is in Phase II clinical trials for use as an adjuvant therapy for HCC after curative surgery, as well as in Phase III trials for the adjuvant treatment of patients with hepatitis virus related hepatocellular carcinoma after surgical resection; and OBP-301, which is in Phase I/II clinical trials to treat cancer. It also develops human native mAbs for therapeutic applications related to infectious diseases; cell-based vaccine products; and nucleic acid testing products for diagnostics in pathogens, personalized medicine, and genetic diseases, as well as provides third-party testing services. In addition, the company offers pharmaceuticals for infectious diseases and contraceptives; health products, such as functional nutrition milk powder and vitamin C tablets; and dermatologic agents and eye care products. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei City, Taiwan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.